drugset / Trial / NCT04890873
ERX1000 - Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Study in Male and Female Subjects With Obesity
RandomizedParallel-groupDouble-blindTreatment
Summary
The primary objective is to assess the safety and tolerability of single and multiple oral doses of ERX1000 in obese subjects.
Timeline
- Start
- 2019-10-17
- Primary completion
- 2023-07-03
- Completion
- 2023-07-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ERX1000 | Unknown | 4 mg | Oral |
| Subject | ERX1000 | Unknown | 8 mg | Oral |